The Research and Development division (R&D) at Biotech is empowered by state-of-the-art facilities focused on producing high quality recombinant therapeutic proteins. The large horizon of technological and scientific expertise enables us to develop new and affordable therapeutics for the world’s most debilitating diseases, such as cancer.
The niche expertise gathered over the decade of experience in frontier biotech sciences, includes cloning, process development (upstream and downstream), advanced analytics and novel drug formulation on various technology platforms, has visible evidences of unparalleled success in launching several high-value products which is an achievement that thrusts Intas foremost and above all competitors.
The R&D labs are fully equipped with most advanced instruments for extensive physico-chemical and bioanalytical product characterization. Diversified talent pool of scientists in R&D plays a pivotal role of developing products, which are transferred to manufacturing facility for commercial production.
Starting with biosimilars, the progression is structured to develop monoclonal antibodies, plasma products and proprietary and innovative recombinant biopharmaceuticals in various thrust areas. Biotech R&D has successfully developed 5 molecules which are already commercialized and there are more than 15 other molecules in R&D at various stages of development. R&D also has more than 25 patent filings to its credit in various areas from clone development to formulation.
Biosimilar Pipeline - Intas Biopharma